Evercore ISI analyst Vijay Kumar is adding Novocure to the firm’s "TAP Underperform" list, citing the view that in the short-term the stock is pricing in "an overly optimistic" outcome for the LUNAR NSCLC readout. Kumar maintains an Underperform rating and $42 price target on Novocure shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVCR: